With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.246047-72-3,(1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium,as a common compound, the synthetic route is as follows.
A suspension of 1.00 g (1.18 mmol) of [RuCl2(PCy3)(ImH2Mes)(phenylmethylene)] (commercially available from Sigma- Aldrich Inc., St. Louis, USA), 0.13 g (1.30 mmol) of copper chloride and 0.36 g (1.30 mmol) of 2-[((?,Z)-2-propenyl)-phenoxy]-l -pyrrolidine- 1-yl- propan-1-one as a 4:1 mixture ofE/Z-isomers in 75 ml of dichloromethane was stirred for 30 min at 400C. The reaction mixture was evaporated to dryness at 400C/ 10 mbar. The residue was
246047-72-3, As the paragraph descriping shows that 246047-72-3 is playing an increasingly important role.
Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; WO2009/124853; (2009); A1;,
Highly efficient and robust molecular ruthenium catalysts for water oxidation
Catalysts | Special Issue : Ruthenium Catalysts – MDPI